Business
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company
About this update from Scisparc Ltd.
[{"type":"text","content":"TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office (the “Patent”). The Patent aligns seamlessly with the Company's proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. This patent grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies. Oz Adler, CEO of SciSparc, commented, “With this patent, we continue to strengthen our global intellectual property rights. SciSparc is a unique company in the cannabis space. We believe we are building value for our investors, as the Company continues to develop technologies for the treatment of central nervous system disorders.\" The Patent covers the compositions and methods for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant. The Patent was granted on account of the unique composition of cannabinoids and n-acylethanolamines and the methods for their use in preventing and treating a variety of cannabinoid-treated conditions. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI- 210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward...